 BOSTON--BUSINESS WIRE--Verastem Oncology Nasdaq:VSTM, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem. Louis proven track record in drug development, including targeting the RAS pathway for treatment of cancer, and his background as a medical oncologist will be invaluable 